The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Ubiquitination of epidermal growth factor receptor (EGFR) is crucial for its endocytosis and downregulation.
• Dysregulation of EGFR signaling is implicated in carcinogenesis, especially in lung cancer.
• The deubiquitinating enzyme ubiquitin-specific protease 2a (USP2a) exhibits oncogenic properties.

Purpose of the Study:

• To investigate the role of USP2a in the regulation of EGFR endocytosis.
• To elucidate the mechanism by which USP2a affects EGFR stability and signaling.
• To explore the clinical relevance of USP2a and EGFR interplay in non-small cell lung cancer.

Main Methods:

• Transient expression of wild-type and mutant USP2a in HeLa cells.
• Assessment of EGFR localization, ubiquitination, and internalization.
• USP2a silencing using siRNA.
• Analysis of USP2a and EGFR protein levels in non-small cell lung cancer tissues.

Main Results:

• Catalytically active USP2a increased plasma membrane-localized EGFR and decreased internalized and ubiquitinated EGFR.
• USP2a silencing reversed these effects, indicating its role in inhibiting EGFR endocytosis.
• USP2a stabilized both wild-type and mutant EGFR, preventing their degradation.
• Co-overexpression of USP2a and EGFR was observed in non-small cell lung cancers.

Conclusions:

• USP2a antagonizes EGFR endocytosis, leading to amplified EGFR signaling.
• USP2a's stabilization of EGFR contributes to its oncogenic activity.
• Targeting deubiquitination pathways, specifically USP2a, may offer a therapeutic strategy for EGFR-overexpressing cancers.